Variable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis Bullosa
DOI:
https://doi.org/10.2340/actadv.v103.4870Keywords:
blistering, epidermolysis bullosa, squamous cell carcinoma, immunotherapy, collagen VIIAbstract
Cutaneous squamous cell carcinoma (cSCC) is a major complication of recessive dystrophic epidermolysis bullosa (RDEB) that has high morbidity and mortality rates and unmet therapeutic needs. The aim of this study was to evaluate the molecular pattern of cSCC and the clinical course of immunotherapy in 2 RDEB patients with multiple advanced cSCC. Clinical course and disease staging were evaluated retrospectively. The tumour tissues were subjected to immunohistochemical staining. DNA from the blood and cSCC samples was subjected to massive parallel sequencing, and somatic mutations were determined. Patient 1 survived for over 2 years as disease control was achieved with cemiplimab and intralesional interleukin-2. The target advanced cSCC demonstrated a high rate of somatic mutations and strong expression of the immune markers, indoleamine 2,3-dioxygenase, programmed cell death protein ligand 1, and lymphocyte-activation gene 3. The patient ultimately succumbed to complications of oesophageal carcinoma. Patient 2 had an undifferentiated cSCC on the foot, which displayed a low mutational burden and did not express immune markers. The tumour progressed quickly even with cemiplimab therapy. These 2 cases underscore the challenges of cSCC treatment for RDEB. Multiple tumours with different molecular and immune profiles occur concomitantly or sequentially, and surgical excision is not always possible because of the anatomical and tissue constraints imposed by the disease itself. In conclusion, programmed cell death protein 1 inhibitors are approved and effective in treating metastatic and locally advanced cSCC. Our experience and the literature suggest that cemiplimab is an option in patients with RDEB if surgery is not. Somatic mutations and the immune microenvironment should be characterized to predict therapeutic response, particularly in aggressive undifferentiated tumours.
Downloads
References
Fine J-D, Johnson LB, Weiner M, Li K-P, Suchindran C. Epidermolysis bullosa and the risk of life-threatening cancers: The National EB Registry experience, 1986-2006. J Am Acad Dermatol 2009; 60: 203-211.
https://doi.org/10.1016/j.jaad.2008.09.035 DOI: https://doi.org/10.1016/j.jaad.2008.09.035
Montaudié H, Chiaverini C, Sbidian E, Charlesworth A, Lacour J-P. Inherited epidermolysis bullosa and squamous cell carcinoma: a systematic review of 117 cases. Orphanet J Rare Dis 2016; 11: 117.
https://doi.org/10.1186/s13023-016-0489-9 DOI: https://doi.org/10.1186/s13023-016-0489-9
Mallipeddi R. Epidermolysis bullosa and cancer. Clin Exp Dermatol 2002; 27: 616-623.
https://doi.org/10.1046/j.1365-2230.2002.01130.x DOI: https://doi.org/10.1046/j.1365-2230.2002.01130.x
Cianfarani F, Zambruno G, Castiglia D, Odorisio T. Pathomechanisms of altered wound healing in recessive dystrophic epidermolysis bullosa. Am J Pathol 2017; 187: 1445-1453.
https://doi.org/10.1016/j.ajpath.2017.03.003 DOI: https://doi.org/10.1016/j.ajpath.2017.03.003
Mellerio JE, Robertson SJ, Bernardis C, Diem A, Fine JD, George R, et al. Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines. Br J Dermatol 2016; 174: 56-67.
https://doi.org/10.1111/bjd.14104 DOI: https://doi.org/10.1111/bjd.14104
Robertson SJ, Orrin E, Lakhan MK, O'Sullivan G, Felton J, Robson A, et al. Cutaneous squamous cell carcinoma in epidermolysis bullosa: a 28-year retrospective study. Acta Derm Venereol 2021; 101: adv00523.
https://doi.org/10.2340/00015555-3875
Harrs C, van den Akker PC, Baardman R, Duipmans JC, Horváth B, van Kester MS, et al. The aggressive behaviour of squamous cell carcinoma in epidermolysis bullosa: analysis of clinical outcomes and tumour characteristics in the Dutch EB Registry. Br J Dermatol 2022; 187: 824-826.
https://doi.org/10.1111/bjd.21769 DOI: https://doi.org/10.1111/bjd.21769
Schäfer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 2008; 9: 628.
https://doi.org/10.1038/nrm2455 DOI: https://doi.org/10.1038/nrm2455
Hoste E, Arwert EN, Lal R, South AP, Salas-Alanis JC, Murrell DF, et al. Innate sensing of microbial products promotes wound-induced skin cancer. Nat Commun 2015; 6: 5932.
https://doi.org/10.1038/ncomms6932 DOI: https://doi.org/10.1038/ncomms6932
Cho RJ, Alexandrov LB, den Breems NY, Atanasova VS, Farshchian M, Purdom E, Nguyen TN, et al. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. Sci Transl Med 2018; 10: eaas9668.
https://doi.org/10.1016/j.jid.2017.07.734 DOI: https://doi.org/10.1016/j.jid.2017.07.734
Condorelli AG, Dellambra E, Logli E, Zambruno G, Castiglia D. Epidermolysis bullosa-associated squamous cell carcinoma: from pathogenesis to therapeutic perspectives. Int J Mol Sci 2019; 20: 5707.
https://doi.org/10.3390/ijms20225707 DOI: https://doi.org/10.3390/ijms20225707
Reimer A, Lu S, He Y, Bruckner-Tuderman L, Technau-Hafsi K, Meiss F, et al. Combined anti-inflammatory and low-dose antiproliferative therapy for squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. J Eur Acad Dermatol Venereol 2020; 34: e1-3.
https://doi.org/10.1111/jdv.15835 DOI: https://doi.org/10.1111/jdv.15835
Kim M, Li M, Intong LR, Tran K, Melbourne W, Marucci D, et al. Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma. Br J Dermatol 2013; 169: 208-210.
https://doi.org/10.1111/bjd.12272 DOI: https://doi.org/10.1111/bjd.12272
Medek K, Koelblinger P, Koller J, Diem A, Ude-Schoder K, Bauer JW, Laimer M. Wundheilungsstörungen während der antitumorösen Therapie mit Cetuximab bei schwerer generalisierter dystropher Epidermolysis bullosa. J Dtsch Dermatol Ges J Ger Soc Dermatol 2019; 17: 448-450.
https://doi.org/10.1111/ddg.13802_g DOI: https://doi.org/10.1111/ddg.13802_g
Piccerillo A, El Hachem M, De Vito R, De Luca EV, Peris K. Pembrolizumab for treatment of a patient with multiple cutaneous squamous cell carcinomas and recessive dystrophic epidermolysis bullosa. JAMA Dermatol 2020; 156: 708-710.
https://doi.org/10.1001/jamadermatol.2020.0304 DOI: https://doi.org/10.1001/jamadermatol.2020.0304
Duong T, Wong D, Barrett A, Price H. Successful use of immunotherapy to treat advanced cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa. BMJ Case Rep 2021; 14: e238966.
https://doi.org/10.1136/bcr-2020-238966 DOI: https://doi.org/10.1136/bcr-2020-238966
Schwieger-Briel A, Trefzer L, Schumann H, Reimer- Taschenbrecker A, Rafei-Shamsabadi D, Meiss F, Has C. Esophageal carcinoma in severe recessive dystrophic epidermolysis bullosa - an underestimated complication? J Eur Acad Dermatol Venereol 2022; 36: e293-e295.
https://doi.org/10.1111/jdv.17826 DOI: https://doi.org/10.1111/jdv.17826
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 2022; 386: 24-34.
https://doi.org/10.1056/NEJMoa2109970 DOI: https://doi.org/10.1056/NEJMoa2109970
Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 2022; 33: 992-1004.
https://doi.org/10.1016/j.annonc.2022.07.003 DOI: https://doi.org/10.1016/j.annonc.2022.07.003
Li Z, Sun G, Sun G, Cheng Y, Wu L, Wang Q, et al. Various uses of PD1/PD-L1 inhibitor in oncology: opportunities and challenges. Front Oncol 2021; 11: 771335.
https://doi.org/10.3389/fonc.2021.771335 DOI: https://doi.org/10.3389/fonc.2021.771335
Khaddour K, Gorell ES, Dehdashti F, Tang JY, Ansstas G. Induced remission of metastatic squamous cell carcinoma with an immune checkpoint inhibitor in a patient with recessive dystrophic epidermolysis bullosa. Case Rep Oncol 2020; 13: 911-915.
https://doi.org/10.1159/000508933 DOI: https://doi.org/10.1159/000508933
Robertson SJ, Orrin E, Lakhan MK, O'Sullivan G, Felton J, Robson A, et al. Cutaneous squamous cell carcinoma in epidermolysis bullosa: a 28-year retrospective study. Acta Derm Venereol 2021; 101: adv00523.
https://doi.org/10.2340/00015555-3875 DOI: https://doi.org/10.2340/00015555-3875
Vasilev P, Kalev D, Karamanliev M, Dimitrov D, Troyanova P, Yordanova I. Cemiplimab treatment of squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. J Dtsch Dermatol Ges 2023; 21: 295-297.
https://doi.org/10.1111/ddg.14980 DOI: https://doi.org/10.1111/ddg.14980
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Laura Trefzer, Maria E. Hess, Lena Scholten, Kristin Technau-Hafsi, Frank Meiss, Melanie Boerries, Cristina Has, David Rafei-Shamsabadi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
